Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seasonal and decadal changes in glycated albumin levels of Japanese blood donors.

Annals of clinical biochemistry·2025

Same author

Sensitization pattern to environmental allergens in a Japanese population.

The journal of allergy and clinical immunology. Global·2023

Same author

Prevalence of inhaled allergen-specific IgE antibody positivity in the healthy Japanese population.

Allergology international : official journal of the Japanese Society of Allergology·2021

Same author

Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation.

Bone marrow transplantation·2021

Same author

Optimal Aspergillus fumigatus and Asp f 1 serum IgG cut-offs for the diagnosis of allergic bronchopulmonary aspergillosis.

Allergology international : official journal of the Japanese Society of Allergology·2020

Same author

Hepatitis A virus and hepatitis E virus prevalence relates to human immunodeficiency virus infection in Japanese male blood donors.

Microbiology and immunology·2020

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Molecular targeted therapeutics for leukemia].

Tadashi Nagai¹

¹Division of Hematology, Department of Medicine, Jichi Medical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|October 20, 2010

Summary

Molecular targeted therapies, including small molecule inhibitors and antibody conjugates, are advancing leukemia treatment by targeting signaling and epigenetic pathways. These innovative approaches aim to enhance therapeutic effectiveness for leukemia patients.

Area of Science:

Molecular biology
Cancer research
Epigenetics

Context:

Leukemia development involves deregulation of cellular signaling and epigenetic pathways.
Recent molecular analyses have identified key targets for therapeutic intervention.

Purpose:

To review molecular targeted therapies for leukemia.
To highlight the development and application of small molecule compounds and antibody conjugates.

Summary:

Small molecule compounds target signaling proteins (e.g., tyrosine kinase inhibitors) and epigenetic regulators (e.g., histone deacetylase and DNA methyltransferase inhibitors).
Monoclonal antibodies, such as anti-CD33 conjugated agents, are used in acute myeloid leukemia (AML) treatment.
Combinatorial effects of these targeted agents are under investigation to optimize treatment strategies.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Experiment Videos

Last Updated: Jun 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Impact:

Molecular targeted therapies hold promise for improving the effectiveness of leukemia treatment.
These therapies offer new avenues for personalized medicine in oncology.